Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

recruiting267%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
recruiting

Chronic Subdural Hematoma Embolization With Detachable Coils

NCT07291427
recruitingnot_applicable

Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM)

NCT06163547
completednot_applicable

Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT)

NCT04372147

Clinical Trials (3)

Showing 3 of 3 trials
NCT07291427

Chronic Subdural Hematoma Embolization With Detachable Coils

Recruiting
NCT06163547Not Applicable

Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM)

Recruiting
NCT04372147Not Applicable

Embolization of the Middle Meningeal Artery for the Prevention of Chronic Subdural Hematoma Recurrence in High Risk Patients (EMPROTECT)

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3